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Abstract: This paper provides recommendations on the management of complications arising 
from intravesical treatment with bacillus Calmette–Guérin (BCG) for nonmuscle-invasive bladder 
tumors. There is minimal recommendations currently available as randomized trials on the side 
effects of intravesical BCG are lacking and severe complications are usually described in case 
reports only. All physicians giving intravesical BCG should be aware of the possible complica-
tions that could arise and how to treat these. The incidence of bladder irritation, general malaise, 
and fever is very high, while severe complications remain rare. Approximately 8% of patients 
have to stop treatment because of these complications. BCG infections and reactions can occur 
anywhere in the body, and may happen straight away or even several months or years after BCG 
treatment, making early diagnosis difficult. Additionally, correct diagnosis is hampered by the 
uncertain appearance of BCG in tissue and body fluid. An essential step in the management 
complications arising from BCG is written information for both the family doctor and the patient 
on the possible adverse events and their management. Recent data demonstrated that none of the 
earlier advocated methods to  prevent BCG toxicity are valid: lowering the dose, tuberculostatic 
drugs, or oxybutynin. Severe complications are treated with three or four tuberculostatics over 
3–12 months, depending on the severity of the situation. Corticosteroids are an essential therapy 
in BCG septicemia. Nonsteroidal anti-inflammatory drugs and corticosteroids can manage 
efficiently the immunological complications.
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Introduction
Bacillus Calmette-Guérin (BCG) has been used to treat nonmuscle-invasive bladder 
tumors for .40 years. It is one of the most successful biotherapies for cancer in use. 
Despite this long clinical experience, the mechanism of its therapeutic effect is still under 
investigation. Available evidence suggest that urothelial cells, including the bladder 
 cancer cells themselves, cells of the immune system, and their secretions both have crucial 
roles in its antitumor effect.1 Several of the side effects are related to this strong immune 
response and others to the fact that living bacteria are instillated in the bladder.
BCG is found to be the most effective prophylactic treatment for patients with 
high-risk nonmuscle-invasive urothelial bladder neoplasms, and its use is therefore 
recommended in international guidelines.2 In intermediate risk disease, it was also 
found more effective than intravesical chemotherapy but its use should be outweighed 
against its potential severe toxicity. BCG has no place in the treatment of low-grade 
urothelial neoplasms except in the rare cases where chemotherapy is unable to reduce 
the recurrence rate of the tumors.3 The severe side effects are a major reason to avoid 
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the use of BCG. Nevertheless, BCG remains an important 
and common treatment to avoid the need for cystectomy in 
urothelial cancer. Every physician treating this disease should 
therefore know how to prevent and manage the complications 
of BCG treatment.
Previous reviews on management of 
BCG complications
A committee of international experts in bladder cancer 
management, known as the International Bladder Cancer 
Group, published practical recommendations for prevention 
and treatment of intravesical BCG adverse events in October 
2008.4 This was based on a review of the literature and to 
a large extent on expert opinion because literature did not 
deliver a level of evidence greater than level 3. As several 
of the authors of this article were also involved in previous 
reviews,5–8 this document reflects the opinions that were 
already published before 2008. Some of their recommen-
dations did not survive. After 2008, prevention of adverse 
events with ofloxacin, lowering BCG dose, and use of oxy-
butynin were not confirmed to be effective in randomized 
trials (see below).
To our knowledge and after a PubMed search from 
 January 2000 to May 2015 with the terms “BCG complica-
tions”, the current article is the last complete review with 
treatment recommendations published.
Frequency and timing of the  
side effects
The largest and most recent published study with BCG, 
including 1,316 patients, is the EORTC study comparing 
one-third dose with full dose BCG and 1 year with 3 years 
of maintenance BCG.9,10 It reports the side effects in a 
standard way, and also a recommendation on the treatment 
of the complication was provided in the study protocol. 
Its  publication on the side effects10 contains interesting 
and recent information on BCG toxicity. Among the 1,316 
patients who started BCG, 62.8% reported local side effects 
and 30.6% had some form of  systemic side effects, from a 
 frequent short period of fever and general malaise to rare 
severe systemic complications. This is in line with the previ-
ous reports on this subject and illustrates the high frequency 
of the side effects.6
The most frequent local side effects in the EORTC study9 
are complaints of BCG-induced cystitis (35%) and bacterial 
infection (23.3%), frequency of more than once per hour 
in 23.6%, and macroscopic hematuria in 22.6%. The most 
frequent systemic side effects were general malaise in 15.5% 
and fever in 8.1%. BCG sepsis was observed in four patients 
(0.3%). In contrast to the general belief that side effects 
increase over time, frequency was similar in the induction 
course (first six instillations), during the first year, and in the 
2 following years. Most treatment discontinuations for severe 
side effects occurred in the first year (6.2% on a total of 7.8% 
discontinuations over the whole treatment period). Severe 
reactions can already appear at the first instillation,11 but 
obviously the side effects are not dependent on the number 
of instillations but upon the host. These results confirm the 
observation of a previous EORTC study (30911) where the 
majority of the side effects occurred within the first year,12 
and still 19% of the patients stopped treatment because of 
toxicity. Obviously, the discontinuation rate diminished with 
increasing experience among urologists with BCG as only 
7.8% stopped treatment in the last study.
Type of severe side effects
Severe side effects continue to be reported in the literature. 
BCG infection or immune reactions can appear wherever in 
the body, in any organ, with very unusual clinical manifesta-
tions in different medical specialties. A review on the subject 
was published in August 201413 and gives an extensive list of 
described severe complications: prostatitis, orchiepididymitis, 
balanitis, osteomyelitis, and acute infectious arthritis at dif-
ferent places in the skeleton, infected orthopedic and vascular 
prostheses, rheumatological complications, mycobacterial 
pneumonia, interstitial pneumonitis due to hypersensitivity, 
hepatitis, nephritis, vasculitis, mycotic aneurisms, dissemi-
nated BCG and septicemia, and finally the local complication 
of ureteral obstruction and bladder contracture. From June 
2014 to May 2015, we found another ten reports on severe 
complications.14–23 So the things that can happen are very rare 
but quite impressive and in any organ of the body.
Difficulties in diagnosis of the  
severe side effects
If the side effects occur shortly after the instillation, the 
relationship with BCG can be made easily. Nevertheless, the 
side effects mostly occur when the patient is already back 
at home and generalists are not familiar with the complica-
tions of BCG. Therefore, it is highly advocated to inform the 
family doctor of the patient on the treatment and its possible 
complications, alarm symptoms, and practical attitude to 
solve the problem.
A second problem is that complications occur late, up to 
years after the treatment, when the urologist, who gives it, is 
no longer involved. Additionally, many of the complications 
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give symptoms elsewhere in the body, and the patient goes 
to specialists who, again, are unfamiliar with BCG mani-
festations or even unaware of this treatment. Therefore, an 
information document should be delivered to each patient 
treated with the possible late complications. This is the way 
we handle it since many years. Although we have no proof, 
we are convinced that this can help to come to a more rapid 
diagnosis by colleagues of other specialties. This is important 
as the outcome of a complication is often dependent on early 
treatment initiation.
Even if a BCG complication is suspected, it may be 
 difficult to prove it. Acid-fast staining, culture, and poly-
merase chain reaction testing are often negative. Tissue 
biopsies and cultures should be performed to evaluate 
noncaseating granuloma formation and the presence of 
Mycobacterium bovis,24 realizing, however, that this has a 
low yield. As a result, a high clinical suspicion is critical in 
order to prevent delays in treatment initiation.22
Differences in adverse events 
among different BCG strains
Side effects seem similar for all BCG strains used (Tice, 
Connaught, Pasteur, RIVM), but frequency differs from 
one study to another. No differences between strains in side 
effects have been noted in a meta-analysis25 and in a recent 
study comparing Tice versus Connaught strain.26 The dose 
and treatment schedules used differ among studies, and 
therefore, comparison among them is difficult. Ideally, the 
dose should be expressed on colony-forming units as there 
are strong variations of factors 1–4 among the commercial 
preparations. Many studies do not mention this information 
and express the dose in milligrams.
Another problem is that the side effects of BCG have 
not been evaluated in a standard way in many studies, 
resulting in large differences in the frequency of local side 
effects of BCG. A classification of these side effects, tak-
ing into account severity and duration, has been proposed 
and validated,7 but this was not commonly applied by the 
urologic community.
Prevention strategies to diminish 
toxicity
Avoid factors favoring side effects
Several of the severe general side effects could be corre-
lated with traumatic instillation or with instillations given 
early after the transurethral resection.27,28 Therefore, it is 
recommended not to start the instillations within the first 
14 days after the resection or when there is still macroscopic 
hematuria, suggesting insufficient healing of the resection 
wound. BCG should not be given after a traumatic cath-
eterization as there is an open wound that can give direct 
access to the blood circulation provoking disseminated 
BCG infection. Many experts suggest delaying treatment 
in the presence of bacterial cystitis because the barrier for 
the BCG to reach the bloodstream is traumatized. However 
severe side effects continue to appear even after respecting 
the aforementioned rules.
Preventive systemic administration of 
tuberculostatic drugs
As BCG strains are sensitive for most tuberculostatic drugs, it 
was logic to explore if its use could diminish the side effects, 
with however possible less efficacy. EORTC study (30911) 
addressed this clinical question. Three days of 300 mg iso-
niazid (or isonicotinylhydrazide [INH]), once daily at the 
occasion of the BCG instillation, could not reduce local or 
systemic toxicity29 and did not influence efficacy on recur-
rence and progression.30,31 However, INH provoked transient 
liver toxicity in several patients. So, the use of prophylactic 
INH is not recommended.
Another prospective, double-blind, placebo-controlled 
multicenter randomized clinical trial32 showed that two doses 
of 200 mg ofloxacin, which is a strong tuberculostatic agent, 
given shortly after BCG instillation, reduced moderate-to-
severe side effects by 18.5%. Compliance to the therapy was 
also better. However, it concerned only 115 patients, divided 
in two groups, which makes definitive conclusions dangerous. 
As the median follow-up was only 1 year, long-term efficacy 
cannot be judged. To our knowledge, further reports on this 
method of prevention did not appear so far, and therefore, it 
cannot (yet) be advocated.
Preventive symptomatic treatment of 
bladder irritation during BCG
As frequency is a major complaint during BCG instillations, 
10 mg oxybutynin extended release, twice a day, has 
been tested in a randomized study versus placebo includ-
ing 50 patients.33 The results were disappointing as the 
significantly worse outcome was in the oxybutynin arm.
Lowering the BCG dose
Low-dose BCG has been tried in an attempt to decrease the 
frequency and severity of the side effects.34 In this study, 
one-third dose BCG was found as effective as a full dose 
in the prevention of recurrence and progression. However, 
patients with multifocal tumors fared better with the standard 
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dose. In a later study, they confirmed similar efficacy of 
one-third dose versus full dose in high-grade and high-risk 
tumors,35 while overall side effects were significantly less. 
However, the number of patients who discontinued BCG for 
toxicity and the severe complications were similar in both 
arms. A third report of the same group found that one-sixth 
dose was significantly less effective than one-third dose,36 
and therefore should not be used. The EORTC showed in 
a Phase II marker lesion study that a quarter dose was still 
effective.37 So, this is probably the lowest dose that can be 
advocated regarding efficacy.
The largest and most recent EORTC study confirms the 
data on efficacy of the one-third dose BCG but cannot confirm 
any difference in adverse events with the full dose.9,10 The 
explanation for these differences in outcome between the 
Spanish and EORTC study is unclear. A major difference in 
the study design was the duration of BCG treatment, which 
was 5 months in the Spanish study and 1–3 years in the 
EORTC study. Anyhow, it is far from evident that a lower 
dose will diminish side effects in general and certainly not 
the severe and most troublesome ones, which are the reason 
for stopping the treatment with BCG.
Use of inactivated BCG
The idea to inactivate BCG by heat, irradiation, or formal-
dehyde in order to prevent its side effects due to the living 
bacteria is already old, but recently was addressed again 
in preclinical studies.38,39 However, one is far from clinical 
application. Anyhow, one may expect that, if inactivated 
BCG keeps its therapeutic effect, the side effects due to the 
immune response will remain.
Treatment of the BCG 
complications
BCG cystitis
Pollakisuria, dysuria, urgency, and hematuria are frequent in 
the first 2 days after BCG instillation and do not need therapy. 
Increased diuresis, to enhance the evacuation of the mycobac-
teria, is advocated without scientific proof of efficacy, but it 
seems logic. When side effects remain for longer time or are 
really intolerable for the patient, symptomatic treatment with 
spasmolytics, anticholinergics, antiphlogistics, and analgesics 
are empirically advised. Except for oxybutynin, which failed 
to be effective,33 none of these drugs have been tested in this 
condition versus placebo. A randomized clinical trial with 
ofloxacin could  diminish local side effects and therefore can 
be recommended in persisting severe cystitis.32 In view of 
the rather high  frequency of associated bacterial cystitis, it is 
worthwhile to make a culture of the urine and to start thereaf-
ter blindly with ofloxacin. This is a pragmatic way of helping 
a patient who is suffering and claiming therapy. Therapy can 
be adjusted when the result of the urine culture is available. 
Anyhow, next instillation should be postponed with at least 
a week. There is little literature on BCG efficacy altered by 
changing the intensity of the therapy, but postponing the 
instillation is the only reasonable solution to keep the patient 
on further BCG treatment. All these recommendations are 
based on expert opinion, taken from the previous reviews, as 
randomized clinical trials or even large observational studies 
on efficacy of the recommended therapies are missing.
General malaise and fever
Again, these frequent side effects resolve mostly within 
48 hours. Symptomatic antipyretics can be given when 
fever exceeds 38°C. Fever .38.5°C for .2 days needs 
close monitoring of the patient and consultation of infectious 
disease specialist in order to see if there are other causes of 
fever. While further diagnostic evaluation, prompt treatment 
with a minimum of two or more tuberculostatic agents (eg, 
fluoroquinolones, INH, rifampicin) is started.4 The duration 
of this therapy is badly defined and depends on further 
evolution of fever, malaise, and other findings at diagnostic 
exploration. Anyhow, further BCG is at least postponed, but 
with a high-risk tumor, the side effects should be weighed 
against the benefits.
Local infections with BCG
BCG can invade the prostate and the seminal vesicles up to 
the epididymis. These diseases require a triple tuberculostatic 
treatment. Often fluoroquinolone is one arm of it. The dura-
tion varies from one study to another from 3 to 6 months. 
Orchiepididymectomy may be a rapid solution for a severely 
symptomatic patient, but it does not replace the general 
tuberculostatic treatment that should be continued.13 In rare 
cases, transurethral resection of the prostate is necessary to 
solve obstruction. Asymptomatic granulomatous prostatitis, 
however, was found to be frequent after intravesical BCG 
therapy but does not require treatment.14
BCG balanitis or contact dermatitis has been described 
and can be handled with local steroids. Careful cleaning of 
hands and genital region after drug handling and voiding 
should prevent it.
Granulomatous balanitis, however, can present with 
multiple erythematous and painless nodules of the glans, 
which should be treated with systemic triple tuberculostatic 
drug therapy.13,40
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Systemic BCG infections
As described earlier, BCG can spread from the bladder in any 
organ in the body and provoke a wide range of manifesta-
tions, shortly or several months after BCG instillation. All 
these conditions require cessation of BCG, if still applicable, 
and a systemic treatment with at least three tuberculostatic 
agents. The duration of the treatment reported in the litera-
ture is variable from 3 months to 1 year, depending on the 
severity of the complication treated. This is based rather on 
expert opinion than on any evidence. In general, a 6-month 
therapy is advocated.
In case of septicemia and multiorgan failure, early high-
dose corticosteroids support is an essential part of the treat-
ment as long as symptoms persist. In these cases, it is also 
recommended to start as many as four tuberculostatic agents 
in order to obtain rapid and trustable response.13
Inadvertent intravenous BCG administration was also 
reported.41 This is due to the dubious instruction from the 
urologist who wrote “IV BCG” (meaning intravesical) for 
an unexperienced nurse.
Tuberculostatic agents
The tuberculostatic drugs that can be used against BCG are 
INH, rifampicin, ethambutol, fluoroquinolones, clarithromy-
cin, aminoglycosides, and doxycycline.42 BCG strains are not 
sensitive to pyrazinamide, and therefore should not be used, 
although mentioned in several articles.
The use of cycloserine is controversial. Although it has 
some survival benefits in mice experiments, the drug seems 
to be inactive against the current strains of BCG.42 Its use 
cannot be recommended.
Monotherapy is never indicated as resistance to one 
drug rapidly appears. Triple drugs, and even four drugs in 
the severe cases, should be used. The drugs are given as a 
single daily dose, all together before breakfast, on an empty 
stomach.
Tolerability and side effects may be a serious problem. 
INH has a well-known liver toxicity, which appears in 
10%–20% of the patients.6 When liver transaminases exceed 
three to five times the normal value, the drug must be stopped. 
It is also recommendable to control the transaminases before 
start of the treatment. Rifampicin can add to the liver toxicity 
and has many interactions with other drugs. Ethambutol can 
provoke optical neuritis. When these drugs are prescribed 
by physicians who are not familiar with those drugs, it is 
advocated to consult the professional websites on that subject 
or to refer patients to colleagues or centers familiar with the 
treatment of tuberculosis.
immunological complications
BCG incites a strong immune reaction, and therefore, immu-
nologically induced diseases and symptoms may be expected. 
More than 89 cases of arthritis and arthralgia provoked by 
BCG have been described in a recent review article,43 and 
a more recent case can be added.15 Polyarthritis is the most 
frequent form of the disease, but one or few articulations can 
be attacked. Mild and short arthralgias, without consequences, 
occurred regularly during a BCG course. Reiter’s syndrome and 
conjunctivitis alone have been described in association with the 
arthritis.44 Immunological reactions at any other organ in the 
body theoretically can be expected and are rarely described.13,23 
The diagnostic workup of these patients may be exhaustive 
given the broad range of causes of similar symptoms.
Nonsteroidal anti-inflammatory drugs and corticosteroids 
are effective in the large majority of the cases with recovery 
within 2 and 6 months, respectively, of 70% and 93% of the 
patients.43
Guidelines on nonmuscle-invasive 
bladder cancer
BCG is a recommended treatment in all the guidelines on 
nonmuscle-invasive bladder cancer. In view of the high num-
ber of side effects and a small number but severe, potentially 
lethal complications, it seems reasonable that they give instruc-
tions on the management of the complications of BCG. This 
review draws attention to the fact that some of the suggested 
methods to prevent BCG toxicity are no longer valid.
An important suggestion is to give written information 
to patients and their general practitioner on the possible 
severe, early, and late complications in any organ of the 
body. Although it has not been proved, it seems a method of 
common sense to improve early detection and therapy.
Conclusion
-	 All physicians giving intravesical BCG should be aware 
of the possible complications and its treatments.
-	 The side effects occur from the first instillation to the last 
one and the incidence is not increasing over time.
-	 The incidence of bladder irritation, general malaise, 
and fever is very high, while severe complications 
remain rare. Following the most recent study, ∼8% of the 
patients have to stop treatment for these complications.
-	 BCG infections and reactions can occur at any organ or place 
in the body, and this can happen shortly or months to years 
after the BCG treatment, making early diagnosis difficult.
-	 Additionally, correct diagnosis is hampered by uncertain 
appearance of BCG in tissues and body fluids.
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-	 An essential step in the management of BCG complica-
tions is written information for the family doctor and 
for the patient on the possible adverse events and their 
management.
-	 Recent data demonstrate that none of the earlier suggested 
methods to prevent BCG toxicity are valid: lowering the 
dose, tuberculostatic drugs, or oxybutynin.
-	 The most common side effects do not need therapy.
-	 Severe complications are treated with three or four tuber-
culostatics during 3–12 months depending on the severity 
of the situation.
-	 Corticosteroids are an essential therapy in BCG 
septicemia. Nonsteroidal anti-inflammatory drugs and 
corticosteroids resolve the immunological complications, 
mostly rheumatological, of BCG.
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